ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1614

The Impact of High Risk Susceptible Gene  LILRA3  on Joint Inflammation in Rheumatoid Arthritis

Mengru Liu1, Yan Du2, Jing Zhang1, Fanlei Hu1, Li Zheng3, Yingni Li3, Jianping Guo1 and Z. Li1, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China, 3Peking University People's Hospital, Beijing, China

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a putatively secreted protein belongs to the leukocyte immunoglobulin-like receptor (LILR) family. Based on our research that LILRA3 is a novel genetic risk for rheumatoid arthritis (RA) in Chinese Han population , we undertake this study to investigate the role of LILRA3 on synovium inflammation  in RA patients.

Methods:  i) The expression of LILRA3 in serum and synovial fluid from patients with RA ,OA, and health controls were measured by using ELISA. ii) Fibroblast-like synoviocytes (FLSs) from RA patients were stimulated with different concentration of recombinant LILRA3 protein in the presence or absence of tumour necrosis factor (TNF)-α and interleukin (IL)-1β. iii) FLSs from patients with RA were transfected with LILRA3 plasmid or control vector and 24 hours later were treated with TNF-α and IL-1β co-culture. The expression of inflammatory mediators, including IL-6,IL-8, MMP-1and MMP-3 was measured by q-PCR array and ELISA. MARKinse signaling pathway activation levels were detected by Western Blotting method. One-way analysis of variance was used to detect the differences between the group means.

Results: Compared with health controls, the expression of LILRA3 in RA and OA serum was high and LILRA3 was specifically express in synovial fluid with RA patients. We demonstrated that LILRA3 can promote the secretion of inflammatory factors independently or synergy with TNF-α and IL-1β both in vitro and in a transfect system. Furthermore, we proved that LILRA3 can promoted synovium inflammation through the activation of the signaling pathways, particularly the ERK and JNK pathways.

Conclusion:

Our data demonstrate that LILRA3 is a potent new pro-inflammatory factor in RA. LILRA3 can aggravates synovium inflammation through MARKinse signaling pathway. These findings may give us some clues for the study on the pathogenesis of RA.


Disclosure: M. Liu, None; Y. Du, None; J. Zhang, None; F. Hu, None; L. Zheng, None; Y. Li, None; J. Guo, None; Z. Li, None.

To cite this abstract in AMA style:

Liu M, Du Y, Zhang J, Hu F, Zheng L, Li Y, Guo J, Li Z. The Impact of High Risk Susceptible Gene  LILRA3  on Joint Inflammation in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-high-risk-susceptible-gene-lilra3-on-joint-inflammation-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-high-risk-susceptible-gene-lilra3-on-joint-inflammation-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology